论文部分内容阅读
为了探讨哮喘的免疫机制及防治措施,本文对50名哮喘患儿进行了临床免疫学研究,检测胸腺素治疗后ERFC、LTT效价结合临床改善情况作为判定胸腺素对哮喘患儿体内细胞免疫状态影响的指标。结果表明:哮喘组ERFC和LTT百分率显著低于健康对照组,体外胸腺素激活ERFC明显提高(P<0.001),胸腺素治疗后,患儿ERFC、LTT明显增高,与正常儿童无差别,哮喘组体外胸腺素激活ERFC增加率与胸腺素治疗后ERFC增加率呈高度正相关(r=0.9226)。支气管哮喘应用免疫调节剂是合理的。
In order to investigate the immune mechanism of asthma and its prevention and treatment measures, 50 immunized children with asthma were studied in this study. The ERTT and LTT titer combined with clinical improvement after thymosin treatment were evaluated as the cellular immunity status of thymosin in asthmatic children Impact indicators. The results showed that the percentage of ERFC and LTT in asthma group was significantly lower than that in healthy controls (P <0.001), ERFC and LTT in thymosin group were significantly higher than those in normal controls The increase rate of extracellular thymosin-activated ERFC was positively correlated with the increase rate of ERFC after thymosin treatment (r = 0.9226). Bronchial asthma application of immunomodulators is reasonable.